EUVIMEDEUVIMED entdecken
FallberichtOpen Access

In Vivo Evolution of Candida auris Multidrug Resistance in a Patient Receiving Antifungal Treatment

Tristan W Wang, Nicole Putnam, J Kristie Johnson, Mary Ann Jabra-Rizk iD

The Journal of Infectious Diseases · 2025

DOI: 10.1093/infdis/jiaf394 ↗

Kurz gefasst

Fallbericht in der Zeitschrift The Journal of Infectious Diseases, 2025. Verfasst von Tristan W Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology and Diagnostic Sciences, School of Dentistry, University of Maryland, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Antifungal Agents, Candida auris, Candidiasis, Drug Resistance, Multiple, Fungal. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIH HHS, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Candida auris is associated with life-threatening invasive disease due to a high level of drug resistance. We present a clinical case of C. auris multidrug resistance development in a patient acquired during antifungal treatment. Five isolates were prospectively recovered from a lung transplant patient receiving antifungal therapy over a 1-year period. While isolates were initially only resistant to fluconazole, the terminal isolate became resistant to caspofungin and amphotericin B with significant increase in micafungin minimum inhibitory concentration. Sequencing of ERG11 and FKS1 genes identified mutations associated with fluconazole and echinocandin resistance in the multidrug-resistant isolate, underscoring the threat of therapy-induced development of resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antifungal AgentsCandida aurisCandidiasisDrug Resistance, Multiple, FungalHumansMaleAmphotericin BCaspofunginEchinocandinsFluconazoleFungal ProteinsLipopeptidesLung TransplantationMicafunginMicrobial Sensitivity TestsMutationAged

Stichwörter der Autor:innen

Candida aurisantifungalsmultidrug resistance developmenttherapy

Substanzen

Amphotericin BAntifungal AgentsCaspofunginEchinocandinsFluconazoleFungal ProteinsLipopeptidesMicafungin

Autor:innen und Institutionen

  • Department of Oncology and Diagnostic Sciences, School of Dentistry, University of Maryland, Baltimore, Maryland, USA.
  • Department of Pathology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • Clinical Microbiology Laboratory, Laboratories of Pathology, University of Maryland Medical Center, Baltimore, Maryland, USA.
  • Department of Microbiology and Immunology, School of Medicine, University of Maryland, Baltimore, Maryland, USA.

ORCID-Profile: Mary Ann Jabra-Rizk

Förderung

  • NIAID NIH HHS
  • NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • University of Maryland Baltimore
  • National Institutes of Health

Zitieren

APA

Wang, T. W., Putnam, N., Johnson, J. K., & Jabra-Rizk, M. A. (2025). In Vivo Evolution of Candida auris Multidrug Resistance in a Patient Receiving Antifungal Treatment. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiaf394

Vancouver

Wang TW, Putnam N, Johnson JK, Jabra-Rizk MA. In Vivo Evolution of Candida auris Multidrug Resistance in a Patient Receiving Antifungal Treatment. The Journal of Infectious Diseases. 2025. doi:10.1093/infdis/jiaf394

BibTeX
@article{Wang2025,
  author = {Wang, Tristan W and Putnam, Nicole and Johnson, J Kristie and Jabra-Rizk, Mary Ann},
  title = {In Vivo Evolution of Candida auris Multidrug Resistance in a Patient Receiving Antifungal Treatment},
  journal = {The Journal of Infectious Diseases},
  year = {2025},
  doi = {10.1093/infdis/jiaf394}
}
Kostenlos starten →